A positive HRD score was validated to be associated with BRCA1/2 mutations and with response to platinum-based agents in the PrECOG 0105 breast cancer cohort (NCT00813956) even in the absence of BRCA1/2 mutations [4]. Here, BRCA1 is linked to breast carcinoma.